
Gilead provides some important information on this investigational therapy.
Ebola virus disease definitions from the World Health Organization definitions could be improved by including contact history and intense fatigue as a key symptom and excluding fever, a new study found.
Efforts to develop a COVID-19 vaccine must not skip important steps during clinical evaluation, experts explain.
Is there an association with adverse outcomes in patients hospitalized with influenza taking NSAIDS?
Why men who have sex with men face social hurdles in seeking PrEP and preventive education.
How regional-based data and advancing preventive options could bolster individual HIV-risk care access.
Mylan Pharmaceuticals also announced that a batch of daptomycin has been recalled due to contamination.
Biopharmaceutical companies create nearly $1 billion fund to aid much needed pipeline for antimicrobial resistance.
Findings were announced during the special COVID-19 sessions of the virtual 23rd International AIDS Conference.
While household transmission of C diff infection is low, there was increased incidence after a familial exposure.
This therapy is associated with lower disease-related costs after treatment, but the costs of other conditions may outweigh total cost reductions over time.
Over 200 scientists issued alert to medical community that COVID-19 is transmissible over longer distances via smaller aerosolized droplets.
A study looking at PrEP population obstacles shows men who have sex with men are more likely to not seek out information nor access to prophylaxis.
Dr. Marc Pitasi, epidemiologist, discusses facilitators of routine HIV screening among primary care physicians.
A small study shows a majority of HIV patients open to both starting ART and follow-up telehealth appointments.
A discussion around new data presented at AIDS 2020 which shows statewide strategies are breaking down barriers.
Investigators in Tanzania trialed modest, automated financial incentives for clinic attendance on viral suppression for patients initiating ART.
In a large study, an examination of patterns of use.
In developing countries with overcrowded hospitals, community pharmacies can relive burden, help HIV patients.
Uncovering interesting findings regarding patients' PrEP regimen.
How much does the current virus crisis share in common with early HIV outbreak scare?
Time interval goes down by 3 months in 3 year period.
Investigators compared characteristics and retention between daily and event-driven PrEP patients to better understand low uptake of event-driven PrEP.
Experts assessed the impact of drug overdoses on people living with HIV in British Columbia, identifying factors associated with mortality using competing risk methodology.
People with HIV are living longer than ever at present time, raising quality of life concerns about later stage medical and psychological challenges comorbidities.
Small study shows HIV patients not at a greater risk for worse outcomes.
The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.
With fostemsavir now available for patients with few options, an expert discusses what challenges MDR-HIV patients face in their care.
With insufficient HIV diagnosis testing in that country, this novel testing could help it reach part of its UNAIDS 90-90-90 targets.
A 34-year-old Brazilian man's HIV was undetectable 57 weeks after ending a heightened regimen of ART.